Company Overview - AtriCure, Inc. has received regulatory approval from China's National Medical Products Administration (NMPA) for its AtriClip Left Atrial Appendage (LAA) Exclusion System, allowing the company to market and sell several models of the AtriClip device in China, thereby expanding access to its cardiac solutions [1] - The AtriClip device is designed to exclude and electrically isolate the left atrial appendage during cardiac surgery, which is crucial for managing atrial fibrillation (Afib) and reducing related complications [1][2] Significance of the Approval - The approval is a significant advancement in providing effective treatments for Afib patients in China, as the left atrial appendage is the primary source of blood clots in these patients [2] - The AtriClip device has been used in over 550,000 procedures worldwide, highlighting its efficacy and unique design [2] - AtriCure plans to collaborate with top medical institutions in China to ensure comprehensive training and support, maintaining high standards of patient care [2] Industry Prospects - The global left atrial appendage closure devices market was valued at $1.6 billion in 2023 and is expected to reach $5.3 billion by 2032, growing at a CAGR of 14.1% [3] - Growth drivers include the increasing prevalence of atrial fibrillation, a strong product pipeline, and government initiatives, supported by a robust healthcare system and specialized cardiac centers [3] Recent Developments - In April, AtriCure introduced the cryoSPHERE+ cryoablation probe, which features advanced insulation technology that decreases freeze times by 25% compared to the previous model [4] - The cryoSPHERE+ is currently in an extended limited launch in the United States, with a full release anticipated by the end of the second quarter [4] Price Performance - AtriCure's shares have declined by 30.8% so far this year, contrasting with a 4.1% rise in the industry and a 17% rise in the S&P 500 during the same period [5]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 par value ATRC NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ ...

AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan William Plovanic - Canaccord Genuity Marie Thibault - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Mike Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Good afternoon and welcome to AtriCure’s First ...

For the quarter ended March 2024, AtriCure (ATRC) reported revenue of $108.85 million, up 16.4% over the same period last year. EPS came in at -$0.25, compared to -$0.23 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $106.52 million, representing a surprise of +2.19%. The company delivered an EPS surprise of -19.05%, with the consensus EPS estimate being -$0.21.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

AtriCure (ATRC) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -19.05%. A quarter ago, it was expected that this medical device maker would post a loss of $0.22 per share when it actually produced a loss of $0.21, delivering a surprise of 4.55%.Over the last four quarters, the company has su ...

Exhibit 99.1 For immediate release May 1, 2024 AtriCure Reports First Quarter 2024 Financial Results • Worldwide revenue of $108.9 million – an increase of 16.4% year over year MASON, Ohio, May 1, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. "We are proud to announce a strong start to 2024, marked by ...

AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Conference Call February 15, 2024 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JP Morgan Simon Negin - UBS Matthew O’Brien - Piper Sandler Sam Eiber - BTIG Joseph Conway - Needham Daniel Stauder - JMP Suraj Kalia - Oppenheimer & Company Operator Good afternoon, and welcome to AtriCure’s ...

AtriCure (ATRC) reported $106.54 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 21%. EPS of -$0.21 for the same period compares to -$0.09 a year ago.The reported revenue represents a surprise of +0.04% over the Zacks Consensus Estimate of $106.5 million. With the consensus EPS estimate being -$0.22, the EPS surprise was +4.55%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

AtriCure (ATRC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this medical device maker would post a loss of $0.30 per share when it actually produced a loss of $0.20, delivering a surprise of 33.33%.Over the last four quarters, the company has sur ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ FORM 10-K _________________________________ ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 ____________________________________ AtriCure, Inc. (Exact name of registrant as specified in i ...